Survey
Quarterly Survey: MASH/NASH and MDGL's Rezdiffra (resmetirom) October 2024
Ticker(s): MDGLThe survey includes 20 Liver disease specialists.
How many NASH/MASH patients do you manage?
Do you prescribe Rezdiffra (resmetirom) in your practice today?
What percentage % of your NASH/MASH patients fall into each fibrosis stage?
- F0:
- F1:
- F2:
- F3:
- F4:
And which stage(s), do you expect to prescribe Rezdiffra, if at all? Select all that apply.
- F0
- F1
- F2
- F3
- F4
- I do not plan to prescribe Rezdriffa
What are you currently using to diagnose fibrosis stage (Fibroscan or similar)?
What percentage % of your NASH/MASH patients do you currently prescribe Rezdiffra?
And of your patients currently on Rezdiffra, what percentage % do you expect to discontinue Rezdiffra in the next year? If you do not current prescribe Rezdiffra please enter 'NA'.
What percentage % of your NASH/MASH patients do you expect to prescribe Rezdiffra at the following timepoints?
- 90 days:
- 1 year:
- 2 years:
- 5 years:
What barriers, if any, do you anticipate in prescribing Rezdiffra to your patients?
Do you expect payers to require proof of F2/F3 staging?
And if so, what methods do you think insurance providers/payors will find acceptable?
Considering the current landscape of NASH treatments, where does Rezdiffra stand in terms of its potential market impact?
How effective do you find Rezdiffra compared to GLP-1 medications? Please be specific.
Please describe how you envision your standard of care in the next few years (e.g., GLP1 + Rezdiffra combination 1L or GLP1 mono therapy 1L). Please be specific.
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Rezdiffra?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
